€0.73
+0.01 (+0.83%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TNG.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 4 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5)Randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: TG4050 | Squamous Cell Carcinoma of Head and Neck | 80 | 2027-12-30 | in 498 d | 2026-01-16 |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersNCT03260023results2025-12-02Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced MalignanciesRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Active, not recruiting | Biological: TG4001 · Drug: Avelumab | HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma | 143 | 2024-09-18actual | — | 2026-02-05 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsNCT04725331Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision following completion of Phase I part not driven by safety reason | Biological: BT-001 · Drug: Pembrolizumab [KEYTRUDA®] | Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer | 31 | 2025-10-22actual | — | 2025-11-21 |
| A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)NCT05788926Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision not related to safety | Drug: TG6050 | Non-small Cell Lung Cancer | 22 | 2025-06-23actual | — | 2025-07-09 |
| A Trial Evaluating TG4050 in Ovarian Carcinoma.NCT03839524results2025-11-14Safety and Tolerability (Adverse Event Reported Per CTCAE v5)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: TG4050 | Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma | 64 | 2024-10-08actual | — | 2025-11-14 |
| Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.NCT03724071Phase I part - Dose-limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study has been terminated after Phase I part on 23 February 2023 | Biological: TG6002 · Drug: Flucytosine (5-FC, Ancotil) | Colorectal Neoplasm, Digestive System Neoplasm | 51 | 2023-02-23actual | — | 2023-06-23 |
| Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerNCT04194034Dose-limiting toxicities (Phase I part)Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study has been terminated after Phase I part on 23 February 2023 | Biological: TG6002 · Drug: Flucytosine (5-FC) | Colorectal Neoplasms | 15 | 2023-02-23actual | — | 2023-06-23 |
| A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)NCT03071094results2021-11-19Phase I: Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459). | Biological: Pexastimogene Devacirepvec (Pexa Vec) · Drug: Nivolumab | Hepatocellular Carcinoma (HCC) | 14 | 2020-09-30actual | — | 2021-11-19 |
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)NCT03353675results2022-01-11Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: TG4010 · Drug: Chemotherapy, Nivolumab | Non Small Cell Lung Cancer Metastatic | 44 | 2019-11-20actual | — | 2022-01-11 |
| Safety and Tolerability of TG1050: A Dose-finding StudyNCT02428400Safety and tolerability of TG1050 administered as single or multiple doses: Overall number of AEs, including SAEs, Grade 3 or 4 AEs, Grade 3 or 4 laboratory abnormalities, and any AE leading to a permanent discontinuation of IMP for any reason.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: TG1050, Placebo | Chronic Hepatitis B | 48 | Nov 2018actual | — | 2018-11-27 |
| Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infectionNCT02355951Immunology analysis: Serum titers of Adenovirus serotypes 5 (Ad5) neutralizing antibodies (nAb)Screening | Not applicable | Completed | Other: blood draw | Chronic Hepatitis B | 166 | Feb 2016actual | — | 2016-02-02 |
| Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung CancerNCT01383148Phase 2: Progression-free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Terminated | Biological: TG4010 · Drug: placebo | Non-Small-Cell Lung Carcinoma | 222 | Jul 2015actual | — | 2017-01-05 |
| Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV PatientsNCT01055821complete early virologic responseRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: pegylated interferon and ribavirin · Biological: TG4040 + SOC, TG4040 + SOC | Chronic Hepatitis C Infection | 140 | Oct 2012actual | — | 2013-08-13 |
| Trial of TG4023 Combined With Flucytosine in Liver TumorsNCT00978107Maximal tolerated doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: MVA-FCU1, flucytosine | Hepatocellular Carcinoma | 16 | Sep 2011actual | — | 2014-07-16 |
| Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung CancerNCT00415818Progression free survival at 6 monthsRandomized · Open-label · Treatment | Phase 2/3 | Completed | Biological: MVA-MUC1-IL2 · Drug: 1st line Chemotherapy | Carcinoma, Non-Small-Cell Lung | 148 | Mar 2010actual | — | 2014-07-16 |
| Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell LymphomaNCT00394693Regression and disappearance of lesionsNon-randomized · Open-label · Treatment | Phase 2 | Completed | Genetic: Adenovirus Interferon gamma | Lymphoma, B-Cell | 13 | Jan 2010actual | — | 2014-07-16 |
| Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C VirusNCT00529321Safety (adverse events, vital signs, physical examination, standard laboratory tests)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: MVA-HCV (Immunotherapy) | Hepatitis C, Chronic | 42 | Sep 2009actual | — | 2010-09-03 |
| Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate CancerNCT00040170Randomized · Open-label · Treatment | Phase 2 | Terminated | Biological: MVA-MUC1-IL2 | Prostatic Neoplasms | 50 | — | — | 2006-11-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19